Acute myocardial infarction (AMI) remains a leading cause of mortality worldwide. Although early revascularization has markedly improved short-term outcomes, the incidence of major adverse cardiovascular events after the index event remains unacceptably high, posing a formidable clinical challenge. Contemporary risk-stratification instruments rely predominantly on a restricted set of conventional clinical variables and therefore fail to capture the full spectrum of individual pathophysiological complexity. To overcome these limitations, the present investigation aims to develop a post-AMI prognostic model that integrates comprehensive multimodal data.
Age ≥18 years old
Presented with myocardial infarction, including NSTEMI and STEMI
Undergoing successful percutaneous coronary intervention.
Subjects who decline protocol-mandated follow-up or withhold informed consent.
Individuals whose expected survival is < 1 year.
Patients with myocardial infarction
Cohort
Prospective
Percutaneous coronary intervention
Procedure/SurgeryPercutaneous coronary intervention
Recurrent myocardial infarction or cardiac death
Patients received recurrent myocardial infarction or cardiac death
Diagnostic performance
Diagnostic performance of the AI-driven multimodal predictive model: area under the receiver-operating characteristic curve (AUC), sensitivity, specificity, overall accuracy, positive predictive value (PPV), and negative predictive value (NPV).
MACE at 24 months
Major adverse cardiovascular events, defined as a compisite of cardiac death, myocardial infarction, target vessel revascularization.
MACE at 60 months
Major adverse cardiovascular events, defined as a compisite of cardiac death, myocardial infarction, target vessel revascularization.
MACE according to pre-specified subgroups
MACE stratified by sex, diabetes status, and chronic kidney disease (CKD) status.
MACE according to physiological status
MACE prediction integrating physiological metrics-angiographic FFR, IMR, MRR, and CFR-of the culprit and non-culprit coronary arteries.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
